AI assistant
Centessa Pharmaceuticals plc — Director's Dealing 2021
Jun 2, 2021
31309_dirs_2021-06-01_a9726d9f-d19e-48d3-b614-33a5487b91d0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2021-05-27
Reporting Person: HUSSAIN IQBAL J (General Counsel)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-19 | Share Option (right to buy) | $5.84 | A | 333559 | Acquired | 2031-02-19 | Ordinary Shares (333559) | Direct |
| 2021-04-20 | Share Option (right to buy) | $9.42 | A | 166779 | Acquired | 2031-04-20 | Ordinary Shares (166779) | Direct |
| 2021-05-27 | Share Option (right to buy) | $20.00 | A | 100000 | Acquired | 2031-05-27 | Ordinary Shares (100000) | Direct |
Footnotes
F1: On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.
F2: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3
F3: 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
F4: Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.
F5: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F6: 25% of the shares subject to such option shall vest and become exercisable on February 1, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.